Literature DB >> 26947449

Comparison of 3 type VII collagen (C7) assays for serologic diagnosis of epidermolysis bullosa acquisita (EBA).

Vannina Seta1, Françoise Aucouturier2, Jonathan Bonnefoy3, Christelle Le Roux-Villet1, Valérie Pendaries4, Marina Alexandre1, Sabine Grootenboer-Mignot5, Michel Heller6, Nicole Lièvre6, Liliane Laroche1, Frédéric Caux1, Matthias Titeux3, Alain Hovnanian7, Catherine Prost-Squarcioni8.   

Abstract

BACKGROUND: Serologic diagnosis of epidermolysis bullosa acquisita (EBA) relies on the detection of circulating autoantibodies to type VII collagen (C7).
OBJECTIVE: We sought to compare the diagnostic performances of a commercialized enzyme-linked immunosorbent assay (ELISA) using C7 noncollagenous (NC) domains (C7-NC1/NC2 ELISA) and indirect immunofluorescence (IIF) biochip test on NC1-C7-expressing transfected cells (IIFT), with a full-length-C7 ELISA developed in our laboratory.
METHODS: C7-NC1/NC2 ELISA, IIFT, and full-length-C7 ELISA were run on 77 nonselected consecutive EBA sera.
RESULTS: C7-NC1/NC2 ELISA, IIFT, and full-length-C7 ELISA were positive, respectively, for: 30%, 27%, and 65% of the 77 sera; 43%, 32%, and 80% of 44 sera labeling the salt-split-skin (SSS) floor (F) by IIF (SSS/F(+)); 9%, 22%, and 47% of 32 SSS/F(-) sera; 28%, 28%, and 58% of classic EBA; 41%, 41%, and 82% of inflammatory EBA; and 18%, 0%, and 55% of mucous-membrane-predominant EBA. Significant differences for all sera were found between: the 2 ELISAs for the 77 sera, SSS/F(+) and SSS/F(-) sera, and IIFT versus full-length-C7 ELISA. LIMITATIONS: The retrospective design was a limitation.
CONCLUSION: C7-NC1/NC2 ELISA and IIFT sensitivities for serologic diagnoses of EBA were low. Full-length-C7 ELISA was significantly more sensitive and could serve as a reference test.
Copyright © 2016 American Academy of Dermatology, Inc. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  autoimmune bullous disease; biochip; enzyme-linked immunosorbent assay; epidermolysis bullosa acquisita; indirect immunofluorescence; sensitivity; serologic diagnosis; type VII collagen

Mesh:

Substances:

Year:  2016        PMID: 26947449     DOI: 10.1016/j.jaad.2016.01.005

Source DB:  PubMed          Journal:  J Am Acad Dermatol        ISSN: 0190-9622            Impact factor:   11.527


  10 in total

Review 1.  Autoimmune Subepidermal Bullous Diseases of the Skin and Mucosae: Clinical Features, Diagnosis, and Management.

Authors:  Kyle T Amber; Dedee F Murrell; Enno Schmidt; Pascal Joly; Luca Borradori
Journal:  Clin Rev Allergy Immunol       Date:  2018-02       Impact factor: 8.667

2.  Rituximab Therapy for Mucous Membrane Pemphigoid: A Retrospective Monocentric Study With Long-Term Follow-Up in 109 Patients.

Authors:  Gérôme Bohelay; Marina Alexandre; Christelle Le Roux-Villet; Ishaï Sitbon; Serge Doan; Isaac Soued; Jason Shourick; Laurie Rousset; Benoît Mellottee; Michel Heller; Nicole Lièvre; Coralie Zumelzu; Florence Morin; Sabine Grootenboer-Mignot; Eric Gabison; Frédéric Caux; Catherine Prost-Squarcioni; Philippe Musette
Journal:  Front Immunol       Date:  2022-06-30       Impact factor: 8.786

Review 3.  Raising Awareness Among Healthcare Providers about Epidermolysis Bullosa and Advancing Toward a Cure.

Authors:  Aaron Tabor; Joseph V Pergolizzi; Guy Marti; John Harmon; Bernard Cohen; Jo Ann Lequang
Journal:  J Clin Aesthet Dermatol       Date:  2017-05-01

4.  Diagnosis of Epidermolysis Bullosa Acquisita: Multicentre Comparison of Different Assays for Serum Anti-type VII Collagen Reactivity.

Authors:  Maike M Holtsche; Nina van Beek; Takashi Hashimoto; Giovanni Di Zenzo; Detlef Zillikens; Catherine Prost-Squarcioni; Matthias Titeux; Alain Hovnanian; Enno Schmidt; Stephanie Goletz
Journal:  Acta Derm Venereol       Date:  2021-03-23       Impact factor: 3.875

5.  Diagnostic Value and Practicability of Serration Pattern Analysis by Direct Immunofluorescence Microscopy in Pemphigoid Diseases.

Authors:  Maike M Holtsche; Nina van Beek; Axel Künstner; Hauke Busch; Detlef Zillikens; Enno Schmidt
Journal:  Acta Derm Venereol       Date:  2021-03-09       Impact factor: 3.875

6.  Accessible Diagnostic Methods to Differentiate between Epidermolysis Bullosa Acquisita and Other Subepidermal Autoimmune Bullous Diseases.

Authors:  Khalaf Kridin
Journal:  Indian J Dermatol       Date:  2018 Sep-Oct       Impact factor: 1.494

Review 7.  Cytoskeletal Regulation of Inflammation and Its Impact on Skin Blistering Disease Epidermolysis Bullosa Acquisita.

Authors:  Zlatko Kopecki; Ralf J Ludwig; Allison J Cowin
Journal:  Int J Mol Sci       Date:  2016-07-13       Impact factor: 5.923

8.  Anti-Type VII Collagen Antibodies Are Identified in a Subpopulation of Bullous Pemphigoid Patients With Relapse.

Authors:  Delphine Giusti; Grégory Gatouillat; Sébastien Le Jan; Julie Plée; Philippe Bernard; Frank Antonicelli; Bach-Nga Pham
Journal:  Front Immunol       Date:  2018-03-21       Impact factor: 7.561

9.  Meta-analysis of the clinical and immunopathological characteristics and treatment outcomes in epidermolysis bullosa acquisita patients.

Authors:  Hiroaki Iwata; Artem Vorobyev; Hiroshi Koga; Andreas Recke; Detlef Zillikens; Catherine Prost-Squarcioni; Norito Ishii; Takashi Hashimoto; Ralf J Ludwig
Journal:  Orphanet J Rare Dis       Date:  2018-09-04       Impact factor: 4.123

Review 10.  Epidermolysis Bullosa Acquisita: The 2019 Update.

Authors:  Hiroshi Koga; Catherine Prost-Squarcioni; Hiroaki Iwata; Marcel F Jonkman; Ralf J Ludwig; Katja Bieber
Journal:  Front Med (Lausanne)       Date:  2019-01-10
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.